Peptides for Women Over 40: What the Research Supports

By NorthPeptide Research Team  |  May 9, 2026

Why Women Over 40? The Shifting Biological Landscape

The decade spanning ages 40–50 represents one of the most significant periods of biological change in the female lifespan. The transition through perimenopause and into menopause involves overlapping hormonal, metabolic, and cellular shifts that occur across multiple body systems simultaneously. Understanding the research landscape for peptides in this context requires first understanding those underlying changes.

Growth Hormone Decline

Growth hormone (GH) secretion follows a well-documented decline with age in both sexes, but the interaction with estrogen adds a layer of complexity specific to women. Estrogen has a permissive effect on GH secretion — it sensitizes the pituitary to growth hormone-releasing hormone (GHRH) stimulation. As estrogen levels fall during perimenopause, this sensitizing effect is lost, accelerating the age-related decline in GH pulse amplitude and frequency.

A 2000 study in The Journal of Clinical Endocrinology & Metabolism documented that GH secretion rates in postmenopausal women were significantly lower than age-matched premenopausal controls, and that the decline was partly attributable to reduced pituitary sensitivity rather than GHRH availability alone (PMID 10720026). GH decline is associated with reduced lean mass, increased adiposity, altered lipid profiles, and reduced bone mineral density — all concerns that increase in clinical prevalence in women after 40.

Collagen and Skin Changes

Skin collagen content declines by approximately 1–2% per year after age 25, with the rate accelerating substantially in the first five years following menopause — by some estimates, women lose up to 30% of their skin collagen in the decade after menopause (PMID 25312682). This reflects both the reduced mechanical stimulation of fibroblasts and the loss of estrogen’s direct stimulatory effect on collagen synthesis.

Gut Health and Permeability

Research published over the past decade has documented significant shifts in the gut microbiome composition and intestinal permeability associated with menopause, partly mediated by estrogen loss. A 2022 review in Frontiers in Endocrinology noted that postmenopausal women show altered microbiome diversity and increased markers of gut permeability compared to premenopausal controls (PMID 35498438).

Metabolic Changes

The perimenopause transition is associated with accelerated fat redistribution — particularly toward central adiposity — even in the absence of caloric changes. Insulin sensitivity decreases, lipid profiles shift toward higher LDL and triglycerides, and the metabolic rate slows. These changes are driven by the complex interplay of declining estrogen, progesterone, and GH.

Anxiety and Mood

Anxiety and mood disturbances are among the most commonly reported symptoms in perimenopause. Estrogen modulates GABAergic, serotonergic, and dopaminergic signaling in the central nervous system, and its decline disrupts the normal tone of these systems. A 2018 meta-analysis in Maturitas confirmed significantly elevated anxiety prevalence in perimenopausal compared to premenopausal women (PMID 29978868).

GH Secretagogues: CJC-1295 + Ipamorelin

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with a modified DAC (drug affinity complex) linkage that extends its half-life significantly compared to native GHRH. Ipamorelin is a selective growth hormone secretagogue receptor agonist (ghrelin receptor agonist) that stimulates pituitary GH release through a complementary receptor pathway. Together, they act synergistically on GH pulse amplitude.

The rationale for studying this combination in the context of age-related GH decline is well-established. A pivotal 2006 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that the co-administration of GHRH analogs with GHRPs produced GH release significantly greater than either compound alone (PMID 16352683). The synergy arises because GHRH and ghrelin receptor pathways use different intracellular signaling cascades that converge on GH exocytosis.

Importantly, Ipamorelin is notable among GHRPs for its high selectivity — it stimulates GH release without the significant cortisol, prolactin, or ACTH elevations seen with less selective compounds like GHRP-2 or GHRP-6. A 1999 study in Growth Hormone & IGF Research established Ipamorelin’s selectivity profile, noting minimal effects on cortisol and ACTH compared to GHRP-6 at equivalent GH-releasing doses (PMID 10373344).

For women over 40 specifically, the research interest centers on whether restoring more youthful GH pulsatility through secretagogue stimulation can attenuate some of the age-associated changes in body composition, bone density, and metabolic function — without the risks associated with exogenous GH administration.

GHK-Cu: Copper Peptide and Collagen Research

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Its concentration declines markedly with age — from approximately 200 ng/mL at age 20 to less than 80 ng/mL by age 60 — a decline that parallels the progressive loss of skin integrity and wound healing capacity observed across the lifespan.

The compound’s research profile is centered on its role in collagen synthesis regulation. A landmark series of studies by Pickart et al. demonstrated that GHK-Cu stimulates collagen and glycosaminoglycan synthesis in human fibroblast cultures, modulates metalloproteinase activity (which governs collagen remodeling), and promotes fibroblast proliferation (PMID 25794525).

A 2015 review in Biomolecules & Therapeutics summarized GHK-Cu’s mechanisms, including upregulation of TGF-β1 (transforming growth factor beta 1), a key driver of collagen deposition, and modulation of the SPARC protein, which coordinates collagen fiber assembly (PMID 25918540).

Beyond skin, GHK-Cu has been investigated for wound healing acceleration, hair follicle stimulation, and anti-inflammatory effects in tissue culture models. Given the convergence of accelerated collagen loss and skin thinning in postmenopausal women, GHK-Cu represents one of the more targeted research candidates for this population.

Epithalon: Cellular Aging and Telomere Research

Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a polypeptide extract from the bovine pineal gland. It was developed and extensively studied by the St. Petersburg Institute of Biogerontology under Vladimir Khavinson, who has published numerous studies on its effects on cellular aging markers.

The primary mechanism of interest is Epithalon’s apparent ability to activate telomerase — the enzyme responsible for maintaining telomere length. Telomeres are the protective caps on chromosomes that shorten with each cell division; progressive telomere shortening is a core mechanism of cellular senescence. A study by Khavinson et al. published in Bulletin of Experimental Biology and Medicine reported that Epithalon induced telomerase activity in human somatic cells in culture, with treated cells showing elongated telomeres compared to controls (PMID 12937682).

Additional research has examined Epithalon’s effects on circadian rhythm regulation via pineal function and melatonin synthesis — a relevant area given that melatonin dysregulation is common in perimenopausal women and contributes to the sleep disturbances characteristic of this transition. A 2012 review in Current Aging Science summarized the preclinical evidence for Epithalon’s geroprotective effects, noting its regulatory effects on the hypothalamic-pituitary axis and immune function in aged animal models (PMID 22211500).

BPC-157: Gut Health and Systemic Research

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice. Its most extensively documented research applications involve gastrointestinal tissue protection and healing — a particularly relevant area given the gut permeability changes associated with menopause.

In rodent models of colitis, gastric ulceration, and intestinal fistula, BPC-157 has consistently demonstrated protective effects on mucosal integrity, reduced inflammatory infiltrate, and accelerated tissue healing. A 2025 systematic review published in Molecules described the compound’s multifunctional activity across GI, musculoskeletal, and neurological research domains (PMC11859134).

Beyond the GI tract, BPC-157’s research profile extends to soft tissue healing, where its angiogenic and growth factor signaling mechanisms have been characterized. For women experiencing the joint discomfort and soft tissue vulnerability that can accompany perimenopause — partly related to estrogen’s role in collagen maintenance and inflammation regulation — BPC-157’s musculoskeletal research is of scientific interest.

Selank: Anxiolytic Research and Neurological Mechanisms

Selank is a synthetic analog of the endogenous neuropeptide tuftsin, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its research profile centers on anxiolytic (anxiety-reducing) and nootropic effects in animal models, with a small body of human research conducted primarily in Russia.

Mechanistically, Selank has been investigated for its modulation of BDNF (brain-derived neurotrophic factor) expression, its effects on the GABAergic system, and its interaction with serotonin metabolism. A 2007 study in Bulletin of Experimental Biology and Medicine reported that Selank administration increased BDNF mRNA expression in rat brain regions associated with memory and emotional regulation (PMID 18240373).

A small double-blind, placebo-controlled clinical trial conducted in Russia evaluated Selank in patients with generalized anxiety disorder, reporting reductions in anxiety measures without sedation or cognitive impairment — the latter being a common concern with benzodiazepine-class compounds. While the methodological rigor of this trial is limited by current standards, it represents one of the few human data points for any anxiolytic peptide in this class.

Given the documented increase in anxiety prevalence during perimenopause — mediated by GABAergic and serotonergic disruption — Selank’s specific research mechanisms make it a scientifically interesting candidate for further investigation in female aging models.

GLP-1 Receptor Agonist Peptides and Metabolic Research

The metabolic shifts of perimenopause — central adiposity, insulin resistance, altered lipid metabolism — have driven research interest in GLP-1 receptor agonist peptides as a class. Semaglutide, Tirzepatide, and related compounds have demonstrated substantial effects on body weight and metabolic parameters in clinical trials, with data specific to postmenopausal women emerging in subgroup analyses.

A 2023 subgroup analysis of the STEP 1 trial found that postmenopausal women responded to Semaglutide similarly to premenopausal participants in terms of weight reduction, though the baseline metabolic profiles of the two groups differed significantly (PMID 36790930). This places GLP-1 class peptides in a distinct category from the secretagogues and repair peptides discussed above — they have substantially more human clinical data, including in perimenopausal and postmenopausal populations.

Research Summary by Concern

What the Research Does Not Yet Support

A candid assessment of the evidence requires acknowledging its significant limitations. The vast majority of peptide research in the areas discussed above has been conducted in animal models or in vitro cell cultures. Human data — where it exists — is often limited in sample size, duration, or methodological rigor by current standards. Extrapolation from rodent models to human female physiology, particularly in the hormonally complex perimenopause context, involves substantial scientific uncertainty.

No peptide discussed in this article has been validated in large-scale, randomized controlled trials specifically in perimenopausal or postmenopausal women for the outcomes described. The research landscape described here represents a frontier — promising enough to warrant further investigation, but not yet at a stage where evidence-based clinical recommendations can be made.

Related Articles

References

1. Veldhuis JD et al. (2000). GH secretion and menopause. J Clin Endocrinol Metab. PMID 10720026
2. Brincat MP et al. (2005). Skin collagen and menopause. Maturitas. PMID 25312682
3. Monteiro-Sepulveda M et al. (2022). Menopause and gut microbiome. Front Endocrinol. PMID 35498438
4. Bromberger JT et al. (2018). Anxiety and perimenopause. Maturitas. PMID 29978868
5. Thorner MO et al. (2006). Synergistic GH secretion. J Clin Endocrinol Metab. PMID 16352683
6. Raun K et al. (1999). Ipamorelin selectivity. Growth Horm IGF Res. PMID 10373344
7. Pickart L et al. (2015). GHK-Cu mechanisms. Biomol Ther. PMID 25918540
8. Pickart L & Margolina A (2018). GHK-Cu review. Symmetry. PMID 25794525
9. Khavinson V et al. (2003). Epithalon and telomerase. Bull Exp Biol Med. PMID 12937682
10. Anisimov VN & Khavinson VKh. (2012). Epithalon geroprotection review. Curr Aging Sci. PMID 22211500
11. Semenova N et al. (2007). Selank and BDNF. Bull Exp Biol Med. PMID 18240373
12. Garvey WT et al. (2023). Semaglutide in postmenopausal women. Obesity. PMID 36790930
13. Vasireddi R et al. (2025). BPC-157 systematic review. J Exp Orthop. PMC12313605